Amgen Research (Munich) GmbH
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT01741792
- Locations
- 🇩🇪
Universititätsklinikum, Würzburg, Germany
🇩🇪Universitätsmedizin, Göttingen, Germany
🇩🇪Universitätsklinikum des Saarlandes, Homburg, Germany
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 93
- Registration Number
- NCT01471782
- Locations
- 🇺🇸
Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States
🇺🇸St Jude Children's Research Hospital, Memphis, Tennessee, United States
🇦🇹St. Anna Kinderspital, Vienna, Austria
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 225
- Registration Number
- NCT01466179
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇩🇪Charité - Campus Benjamin Franklin, Berlin, Germany
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT01209286
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 116
- Registration Number
- NCT01207388
- Locations
- 🇷🇴
2105 - Institutul Regional de Oncologie, Iasi, Romania
🇦🇹1107 - Krankenhaus der Elisabethinen, Linz, Austria
🇮🇹1309 - Azienda Ospedaliera Antonio Cardarelli, Napoli, Italy
Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2011-11-11
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 35
- Registration Number
- NCT00866944
- Locations
- 🇩🇪
Klinikum der Johannes-Gutenberg Universität, Mainz, Germany
🇩🇪Klinikum Mannheim GmbH Universitätsklinikum, Mannheim, Germany
🇩🇪Universitätsklinikum der LMU Grosshadern, München, Germany
A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)
- Conditions
- Interventions
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 66
- Registration Number
- NCT00756860
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 65
- Registration Number
- NCT00635596
- Locations
- 🇩🇪
University Hospital Hamburg-Eppendorf, Hamburg, Germany
🇩🇪Hospital Kassel, Kassel, Germany
🇩🇪University Hospital Würzburg, Würzburg, Germany
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 21
- Registration Number
- NCT00560794
- Locations
- 🇩🇪
Klinikum der J.W. Goethe Universität, Frankfurt, Hessen, Germany
🇩🇪Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany
🇩🇪Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany
Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
- Conditions
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 76
- Registration Number
- NCT00274742
- Locations
- 🇩🇪
Universitätsklinikum Essen, Klinik für Hämatologie, Medizinische Klinik und Poliklinik, Essen, Germany
🇩🇪Universtätsklinkum Tübingen, Tübingen, Germany
🇩🇪Medizinische Klinik 5, Hämatologie & Internistische Onkologie, Universitätsklinikum Erlangen, Erlangen, Germany